 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper   
127th MAINE LEGISLATURE  
 
FIRST REGULAR SESSION -2015  
 
Legislative Document  No. 919  
H.P. 638  House of Representatives, March 17, 2015  
 
 
An Act To Provide Access to Opioid Analgesics with Abuse -
deterrent Properties  
 
 
 
 
Reference to the Committee on Insurance and Financial Services suggested and ordered 
printed.  
 
 
  
 ROBERT B. HUNT  
 Clerk  
 
Presented by Representative HOBBINS of Saco.  
Cosponsored by Representative: GIDEON of Freeport, Senators: KATZ of Kennebec, VOLK 
of Cumberland.  
 
 

 
 Page 1 - 127LR1724(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  24-A MRSA ยง4320 -J is enacted to read:  2 
ยง4320 -J.  Coverage for abuse -deterrent opioid analgesic drug products  3 
1.  Definitions.   As used in this section, unless the context otherwise indi cates, the 4 
following terms have the following meanings.  5 
A.  "Abuse -deterrent opioid analgesic drug product" means a brand or generic opioid 6 
analgesic drug product approved by the federal Food and Drug Administration with 7 
abuse -deterrent labeling claims tha t indicate the drug product is expected to result in 8 
a meaningful reduction in abuse.  9 
B.  "Cost sharing" means any coverage limit, copayment, coinsurance, deductible or 10 
other out -of-pocket expense associated with a health plan.  11 
C.  "Opioid analgesic drug p roduct" means a drug product in the opioid analgesic 12 
drug class prescribed to treat moderate to severe pain or other conditions, whether in 13 
immediate release or extended release, long -acting form and whether or not 14 
combined with other drug substances to fo rm a single drug product or dosage form.  15 
2.  Required coverage.   A carrier offering a health plan in this State shall provide 16 
coverage for abuse -deterrent opioid analgesic drug products as preferred drugs on any 17 
formulary, preferred drug list or other list  of drugs used by the carrier. Any cost sharing 18 
imposed by a carrier for coverage of abuse -deterrent opioid analgesic drug products may 19 
not exceed the lowest cost -sharing level applied to other prescription drugs. An increase 20 
in enrollee cost sharing or ot her disincentives for prescribers or dispensers to achieve 21 
compliance with this section may not be implemented.  22 
3.  Utilization management.  The following requirements apply.  23 
A.  Any prior authorization requirements or other utilization review measures for  24 
opioid analgesic drug products on the market and any denials of coverage made 25 
pursuant to those measures may not require use of opioid analgesic drug products 26 
first in order to obtain abuse -deterrent opioid analgesic drug products.  27 
B.  This section may no t be construed to prevent a carrier from applying prior 28 
authorization requirements to abuse -deterrent opioid analgesic drug products as long 29 
as such requirements are applied to opioid analgesic drug products in the same 30 
manner.  31 
Sec. 2.  Application. The re quirements of this Act apply to all policies, contracts 32 
and certificates executed, delivered, issued for delivery, continued or renewed in this 33 
State on or after January 1, 2016.  For purposes of this Act, all contracts are deemed to be 34 
renewed no later th an the next yearly anniversary of the contract date.  35 
SUMMARY  36 
This bill requires all health insurance carriers offering individual and group health 37 
plans to provide coverage for abuse -deterrent opioid analgesic drug products as preferred 38 
 
 Page 2 - 127LR1724(01) -1 
 drugs on any formul ary, preferred drug list or other list of drugs used by the carrier. The 1 
bill applies to all policies and contracts issued or renewed on or after January 1, 2016.  2 
 
